The Influence of Hormone Therapy on the Development of Pulmonary Fibrosis after Radiotherapy in Patients with Breast Cancer

Basit Öğe Kaydı
dc.contributor.authorYavuz, Berrin Benli
dc.contributor.authorPoyraz, Necdet
dc.contributor.authorKanyilmaz, Gul
dc.contributor.authorAktan, Meryem
dc.contributor.authorTuncez, Ismail H.
dc.contributor.authorKoc, Mehmet
dc.date.accessioned2024-02-23T14:40:52Z
dc.date.available2024-02-23T14:40:52Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractThe aim of the present study is to investigate the effects of hormone therapy on pulmonary fibrosis in patients who received curative conformal radiotherapy for breast cancer. Data of 469 patients were evaluated. Computerized tomography images were evaluated by a radiologist as blindly. The influence of hormone therapy (tamoxifen and aromatase inhibitors), age, menopause, radiotherapy fields, ipsilateral lung volume receiving 5 Gy (V5), ipsilateral lung volume receiving 20 Gy (V20), ipsilateral mean lung dose (MLD) and the effects of taxane group of chemotherapy on pulmonary fibrosis were investigated. The mean age was 51 (range 27-83) years. As hormone therapy, 159 patients (33.9%) used tamoxifen and 253 patients (53.9%) used aromatase inhibitors. A significant relationship was found between both 6th month lung fibrosis and 2nd year lung fibrosis, and V5, V20, MLD, regional lymphatic irradiation and hormone therapy use. More grade 2 fibrosis was detected in the patients who received tamoxifen compared to the patients who received aromatase inhibitors and the control group (p< 0.001). No association was found between menopausal status, age, and taxane group chemotherapy and lung fibrosis development. In multivariate analysis, V5, MLD, and using hormone therapy were shown to be independent predictors of the risk of developing fibrosis at both 6 months and 2 years. Use of tamoxifen increases early and late lung fibrosis more than aromatase inhibitors in patients who receive radiotherapy for breast cancer. However, V5, V20, MLD and regional lymph node irradiation also contribute to the prevalence of fibrosis.en_US
dc.identifier.doi10.4999/uhod.226171
dc.identifier.endpage165en_US
dc.identifier.issn1306-133X
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85134070806en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage159en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.226171
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16623
dc.identifier.volume32en_US
dc.identifier.wosWOS:000824359700004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Canceren_US
dc.subjectTamoxifenen_US
dc.subjectAromatase Inhibitorsen_US
dc.subjectPulmonary Fibrosisen_US
dc.titleThe Influence of Hormone Therapy on the Development of Pulmonary Fibrosis after Radiotherapy in Patients with Breast Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu